Company
Every investor coverage indicates participated in a round Centocor/Janssen raised.
Companies Centocor/Janssen acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Dan Baker | Vice President, Immunology (former) | OneVentures portfolio |
Stories naming Centocor/Janssen. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane immunology company Kira Biotech has launched with a $20 million Series A, OneVentures leading alongside IP Group and Queensland government support, to progress its lead antibody KB312 into early human studies.